Skip to main content

Table 5 Studies analyzing cancer risk in patients with primary SjS based on the fulfillment of the 2002 criteria

From: Characterization and risk estimate of cancer in patients with primary Sjögren syndrome

Author Year Country Setting Primary SjS patients (n) Mean folow-up (yrs/pat-years) Population cancer registry/classif Hemat neoplasia classif Cancer (n) All-cancer SIR (95% CI) Specific solid cancer SIR Hemat cancers (n) NHL (n) MALT (n) DLBC (n) MZ (n) Myel (n) Other B-cell Non-B-cell NHL SIR (95% CI) MM SIR (95% CI)
Theander 2006 Sweden Hosp 286 jul-64 Swedish Cancer Reg/ICD7 WHO 2001 33 1.42 (0.98–2.00) NA 12 11 1 7 0 2 1 T-cell (1) 15.6 (7.8–27.8) 3.27 (0.1–18.2)
Baimpa 2009 Greece Hosp 536 2.6/ND NA ND ND NA NA 40 38 21 7 5 0 5 HD (1), T-cell (1) NA ND
Zhang 2010 China Hosp 1320 4.4/ND Shangai Reg/ICD10 WHO 2001 29 3.25 (2.12–4.52) NA 10 8 2 2 0 0 3 T-cell (1) 48.1 (20.7–94.8) 37.9 (4.58–136.7)
Weng 2012 Taiwan Pop 7852 ND/27246 NHI/ICD9 ICD9 227 1.01 (0.74–1.35) Colon 0.22 (0.05–0.6); Thyroid 2.56 (1.4–4.3) 31 23 ND ND ND ND ND ND 7.1 (4.2–10.3) 6.1 (2.0–14.2)
Baldini 2012 Italy Hosp 563 6/ND NA WHO 2001 NA NA NA NA 12 8 3 1 0 0 ND NA ND
Hemminki 2012 Sweden Pop 1516 ND/16700 Swedish Cancer Reg/ICD NA NA NA Breast 0.46 (0.26–0.75) NA NA ND ND ND ND ND ND NA ND
Johnsen 2013 Norway Pop 443 ND/3813 Norway Reg/ICD10 ICD10 NA NA NA NA 7 6 0 1 0 0 ND 9.0 (7.1–26.3) ND
Risselada 2013 Netherl Hosp 195 7.7/ND NA WHO 2001 NA NA NA NA 21 10 8 3 0 0 ND NA ND
Quartuccio 2014 Italy Hosp 661 ND NA ND NA NA NA NA 40 ND ND ND ND ND ND NA ND
Papageorgiou 2015 Greece Hosp ND ND ND WHO ND ND ND ND 77 51 12 8 0 6   ND  
Nocturne 2016 France Hosp ND ND ND WHO ND ND ND ND 99 58 17 18 0 6 HD (1), T-cell (1) ND ND
Present study 2016 Spain Hosp 1300 7.6/ND GLOBOCAN/ICD10 WHO 2016 122 1.91 (1.6–2.28) Thyroid 5.17 (1.94–13.79); Lip/oral 4.81 (1.81–12.83); Stomach 2.53 (1.05–6.07) 61 12 27 7 4 2 6 HD (4), T-cell (3), myeloid/leuk (8) 6.04 (3.43–10.64) 36.17 (25.44–51.43)
  1. ND not detailed, NA non-applicable, MALT mucosa-associated lymphoid tissue, DLBC Diffuse large B-cell lymphoma, MZ marginal zone lymphoma, MM myeloma multiple, Netherl Netherlands, Hosp hospital, Pop population, Classif classification, Hemat hematological, Myel Myeloma